 |
Oncology Archives 1. Antonarakis ES,
Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic
castration-resistant prostate cancer. Cancer Lett. 2009 Aug 28. [Epub
ahead of print] 2. Antonarakis ES, Heath EI, Walczak JR, Nelson
WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus
RT, Baker SD, Parnes HL, Deweese TL, Partin AW, Carducci MA. Phase II,
Randomized, placebo-controlled trial of neoadjuvant celecoxib in men
with clinically localized prostate cancer: evaluation of drug-specific
biomarkers. J Clin Oncol. 2009 Aug 31. [Epub ahead of print] 3. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW.
Dual inhibition of mitogen-activated protein kinase kinase and mammalian
target of rapamycin in differentiated and anaplastic thyroid cancer.
J Clin Endocrinol Metab. 2009 Sep 1. [Epub ahead of print] 4. Lo PK, Watanabe H, Cheng PC, Teo WW, Liang
X, Argani P, Lee JS, Sukumar S. MethySYBR, a novel quantitative PCR
assay for the dual analysis of DNA methylation and CpG methylation density.
J Mol Diagn. 2009 Sep;11(5):400-14. 5. Pan F, Yu H, Dang EV, Barbi J, Pan X, Grosso
JF, Jinasena D, Sharma SM, McCadden EM, Getnet D, Drake CG, Liu JO,
Ostrowski MC, Pardoll DM. Eos mediates Foxp3-dependent gene silencing
in CD4+ regulatory T cells. Science. 2009 Aug 28;325(5944):1142-6. Epub
2009 Aug 20. 6. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan
CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, Lorusso PM, Von
Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog
pathway inhibitor GDC-0449. N Engl J Med. 2009 Sep 17;361(12):1173-8.
Epub 2009 Sep 2. 7. Yoshimura K, Meckel KF, Laird LS, Chia CY,
Park JJ, Olino KL, Tsunedomi R, Harada T, Iizuka N, Hazama S, Kato Y,
Keller JW, Thompson JM, Chang F, Romer LH, Jain A, Iacobuzio-Donahue
C, Oka M, Pardoll DM, Schulick RD. Integrin alpha2 mediates selective
metastasis to the liver. Cancer Res. 2009 Sep 15;69(18):7320-8. Epub
2009 Sep 8. 1. Drake CG. Immunotherapy
for prostate cancer: walk, don't run. J Clin Oncol. 2009 Jul 27. [Epub
ahead of print] 2. Gamper CJ, Agoston AT, Nelson WG, Powell JD.
Identification of DNA methyltransferase 3a as a T cell receptor-induced
regulator of Th1 and Th2 differentiation. J Immunol. 2009 Aug 15;183(4):2267-76.
3. Goodman SN. Building a Bayesian bridge from
evidence to guidelines. Arch Intern Med. 2009 Aug 10;169(15):1436-7.
4. Higgins MJ, Park BH. Expanding role of bisphosphonates
in the management of early breast cancer. Expert Rev Anticancer Ther.
2009 Aug;9(8):1051-4. 5. Holdhoff M, Schmidt K, Donehower R, Diaz LA
Jr. Analysis of circulating tumor DNA to confirm somatic KRAS mutations.
J Natl Cancer Inst. 2009 Jul 29. [Epub ahead of print] 6. Keizman D, Carducci MA. Intermittent androgen
deprivation-questions remain. Nat Rev Urol. 2009 Aug;6(8):412-4. 7. Mohammad HP, Cai Y, McGarvey KM, Easwaran H,
Van Neste L, Ohm JE, O'Hagan HM, Baylin SB. Polycomb CBX7 promotes initiation
of heritable repression of genes frequently silenced with cancer-specific
DNA hypermethylation. Cancer Res. 2009 Aug 1;69(15):6322-30. 8. Noronha SA, Farrar JE, Alonzo TA, Gerbing RB,
Lacayo NJ, Dahl GV, Ravindranath Y, Arceci RJ, Loeb DM. WT1 expression
at diagnosis does not predict survival in pediatric aml: A report from
the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jul 17. [Epub
ahead of print] 9. Pardoll D. Metastasis-promoting immunity: when
T cells turn to the dark side. Cancer Cell. 2009 Aug 4;16(2):81-2. 10. Sedelaar JP, Isaacs JT. Tissue culture media
supplemented with 10% fetal calf serum contains a castrate level of
testosterone. Prostate. 2009 Aug 12. [Epub ahead of print] PubMed 11. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM,
Isaacs WB, Drake CG. Human prostate-infiltrating CD8(+) T lymphocytes
are oligoclonal and PD-1(+). Prostate. 2009 Aug 7. [Epub ahead of print]
12. Yu W, Kanaan Y, Baed YK, Gabrielson E. Chromosomal
changes in aggressive breast cancers with basal-like features. Cancer
Genet Cytogenet. 2009 Aug;193(1):29-37. 13. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt
P, Rajagopalan H, Schmidt K, Wilson JK, Markowitz S, Zhou S, Diaz LA
Jr, Velculescu V, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos
N. Glucose Deprivation Contributes to the Development of KRAS Pathway
Mutations in Tumor Cells. Science. 2009 Aug 6. [Epub ahead of print]
1. Balmanoukian A,
Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting 2. Casero RA, Pegg AE. Polyamine catabolism and
disease. Biochem J. 2009 Jul 15;421(3):323-38. 3. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews
KL, Xiao B, Worley PF, Kozma SC, Powell JD. The mTOR kinase differentially
regulates effector and regulatory T cell lineage commitment. Immunity.
2009 Jun 19;30(6):832-44. 4. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar
EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht
J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado
I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. Early epigenetic
changes and DNA damage do not predict clinical response in an overlapping
schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Blood. 2009 Jun 22. [Epub ahead of print] 5. Jack GD, Zhang L, Friedman AD. M-CSF elevates
c-Fos and phospho-C/EBP{alpha}(S21) via ERK whereas G-CSF stimulates
SHP2 phosphorylation in marrow progenitors to contribute to myeloid
lineage specification. Blood. 2009 Jul 8. [Epub ahead of print] 6. Higgins MJ, Stearns V. Understanding resistance
to tamoxifen in hormone receptor-positive breast cancer. Clin Chem.
2009 Jun 18. [Epub ahead of print] 7. Merchant AA, Matsui W. Smoothening the controversial
role of hedgehog in hematopoiesis. Cell Stem Cell. 2009 Jun 5;4(6):470-1.
8. Nelson WG, De Marzo AM, Yegnasubramanian S.
Minireview: Epigenetic alterations in human prostate cancers. Endocrinology.
2009 Jun 11. [Epub ahead of print] 9. Rajeshkumar NV, Tan AC, De Oliveira E, Womack
C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith
WA, Hidalgo M. Antitumor effects and biomarkers of activity of AZD0530,
a Src inhibitor, in pancreatic cancer. Clin Cancer Res. 2009 Jun 15;15(12):4138-46.
Epub 2009 Jun 9. 10. Rau R, Brown P. Nucleophosmin (NPM1) mutations
in adult and childhood acute myeloid leukaemia: towards definition of
a new leukaemia entity. Hematol Oncol. 2009 Jul 1. [Epub ahead of print]
11. Swinnen LJ. Primary central nervous system
lymphoma: recent progress, many remaining questions. Curr Opin Oncol.
2009 Jul 9. [Epub ahead of print] 12. Vander Griend DJ, Konishi Y, De Marzo AM,
Isaacs JT, Meeker AK. Dual-label centromere and telomere FISH identifies
human, rat, and mouse cell contribution to Multispecies recombinant
urogenital sinus xenografts. Prostate. 2009 Jun 26. [Epub ahead of print]
1. Ambinder RF. The same but different: autologous
hematopoietic stem cell transplantation for patients with lymphoma and
HIV infection. Bone Marrow Transplant. 2009 May 18. [Epub ahead of print]
2. Fackler MJ, Rivers A, Teo WW, Mangat A, Taylor
E, Zhang Z, Goodman S, Argani P, Nayar R, Susnik B, Sukumar S, Khan
SA. Hypermethylated genes as biomarkers of cancer in women with pathologic
nipple discharge. Clin Cancer Res. 2009 Jun1;15(11):3802-11. Epub 2009
May 26. 3. Grosso JF, Goldberg MV, Getnet D, Bruno TC,
Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG. Functionally
distinct LAG-3 and PD-1 subsets on activated and chronically stimulated
CD8 T cells. J Immunol. 2009 Jun1;182(11):6659-69. 4. Schafer E, Chen A, Arceci RJ. Sustained first
remission in an adolescent with hepatosplenic T-cell lymphoma treated
with T-cell leukemia induction, nucleoside analog-based consolidation,
and early hematopoietic stem cell transplant. Pediatr Blood Cancer.
2009 May 28. [Epub ahead of print] 5. Wada S, Yoshimura K, Hipkiss EL, Harris TJ,
Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders
R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity:
studies in an autochthonous prostate cancer model.Cancer Res. 2009 May
15;69(10):4309-18. Epub 2009 May 12. 1. Friedman AD. Cell cycle and developmental control
of hematopoiesis by Runx1. J Cell Physiol. 2009 Feb 23. [Epub ahead
of print] 2. Kowalski J, Gange SJ, Schneider MF, Tsai HL,
Templeton A, Shao Q, Zhang GW, Yeh MF, Young M, Markham RB. Relationship
of injection drug use, antiretroviral therapy resistance, and genetic
diversity in the HIV-1 pol gene. J Acquir Immune Defic Syndr. 2009 Feb
12. [Epub ahead of print] 3. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo
M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P,
Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein
AP, Hruban RH, Hidalgo M, Laheru D. DPC4 Gene status of the primary
carcinoma correlates with patterns of failure in patients with pancreatic
cancer. J Clin Oncol. 2009 Mar 9. [Epub ahead of print] 4. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang
X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue
CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein
B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2
as a pancreatic cancer susceptibility gene. Science. 2009 Mar 5. [Epub
ahead of print] 5. Zhu J, Liao G, Shan L, Zhang J, Chen MR, Hayward
GS, Hayward SD, Desai P, Zhu H. Protein array identification of substrates
of the Epstein-Barr virus protein kinase BGLF4. J Virol. 2009 Feb 25.
[Epub ahead of print] 1. Gustin JP, Karakas
B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A,
Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins
MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates
multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009 Feb 5. [Epub
ahead of print] 2. Henson BW, Perkins EM, Cothran JE, Desai P. Self-assembly
of Epstein-Barr virus capsids. 3. Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns
V. Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?
J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. 4. Jimeno A, Feldmann G, Suárez-Gauthier
A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García
E, López-Ríos F, Matsui W, Maitra A, Hidalgo M. A direct
pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic
development. Mol Cancer Ther. 2009 Feb;8(2):310-4. Epub 2009 Jan 27. 5. Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins
B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M, Lemas MV, Brennan
S, Ambinder RF, Matsui W. Circulating clonotypic B cells in classical
Hodgkin's lymphoma. Blood. 2009 Feb 2. [Epub ahead of print] 1. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD,
Grossman SA. Association between hyperglycemia and survival in patients
with newly diagnosed glioblastoma. J Clin Oncol. 2009 Jan 12. [Epub ahead
of print] 2. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene
as a mutated target for cancer therapy. 3. Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse
J, Solomon A, Chan F, Zhao M,Cosenza SC, Reddy MR, Rudek MA, Kulesza P,
Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator
ON 01910.Na in pancreatic cancer and preclinical development of an ex
vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. 4. Larson AR, Konat E, Alani RM. Melanoma biomarkers:
current status and vision for the future. 5. Ochs MF, Casagrande JT. Information systems
for cancer research. Cancer Invest. 2008 Dec;26(10):1060-7. 1. Anchoori RK, Kortenhorst MS, Hidalgo M, Sarkar
T, Hallur G, Bai R, Diest PJ, Hamel E, Khan SR. Novel microtubule-interacting
phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy.
J Med Chem. 2008 Sep 9. [Epub ahead of print] 2. Desai P, Sexton GL, Huang E, Person S. Golgi
localization of herpes simplex virus type 1 UL37 requires UL36 but not
capsid structures. J Virol. 2008 Sep 10. [Epub ahead of print] 3. Ettinger DS, Grunberg SM, Hauber AB, Mohamed
AF. Evaluation of the relative importance of chemotherapeutic and antiemetic
efficacy in various oncologic settings. Support Care Cancer. 2008 Sep
2. [Epub ahead of print] 4. Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong
JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF.
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated
tumors. Nat Med. 2008 Sep 7. [Epub ahead of print] 5. Howell JE, Szabatura AH, Hatfield Seung A, Nesbit
SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity
with concomitant aprepitant. J Oncol Pharm Pract. 2008 Sep;14(3):157-62. 6. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse
J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower
RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified
continuous reassessment method-based, dose-finding study of rapamycin
in adult patients with solid tumors. J Clin Oncol. 2008 Sep 1;26(25):4172-9. 7. Kim JS, Bonifant C, Bunz F, Lane WS, Waldman
T. Epitope tagging of endogenous genes in diverse human cell lines. Nucleic
Acids Res. 2008 Sep 10. [Epub ahead of print] 8. Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith
W, Erlichman C, Pelley R, Jimeno A, Donehower R, Boni J, Abbas R, Martins
P, Zacharchuk C, Hidalgo M. A phase I study of EKB-569 in combination
with capecitabine in patients with advanced colorectal cancer. Clin Cancer
Res. 2008 Sep 1;14(17):5602-9. 9. Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park
MH, Yoon JH, Zhang Z, Argani P, Sukumar S. Quantitative promoter hypermethylation
profiles of ductal carcinoma in situ in North American and Korean women:
Potential applications for diagnosis. Cancer Biol Ther. 2008 Sep 4;7(9).
[Epub ahead of print] 10. Nguyen P, Bar-Sela G, Sun L, Bisht KS, Cui H,
Kohn E, Feinberg AP, Gius D. BAT3 and SET1A form a complex with CTCFL/BORIS
to modulate H3K4 histone dimethylation and gene expression. Mol Cell Biol.
2008 Sep 2. [Epub ahead of print] 11. Parsons DW, Jones S, Zhang X, Lin JC, Leary
RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon
R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H,
Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM,
Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G,
Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis
of human glioblastoma multiforme. Science. 2008 Sep 4. [Epub ahead of
print] 1. Abukhdeir AM, Park
BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev
Mol Med. 2008 Jul 1;10:e19. 2. Chen H, Shah AS, Girgis
RE, Grossman SA. Transmission of glioblastoma multiforme after bilateral
lung transplantation. J Clin Oncol. 2008 Jul 1;26(19):3284-5. 3. Drake CG. Immunotherapy
for metastatic prostate cancer. Urol Oncol. 2008 Jul-Aug;26(4):438-44.
Epub 2007 Dec 21. 4. Eisenberger MA. Evolving
new treatments for patients with prostate cancer: The advanced disease
paradigm of the PSA era. Urol Oncol. 2008 Jul-Aug;26(4):406-7. 5. El-Shami K, Smith
BD. Immunotherapy for myeloid leukemias: current status and future directions.
Leukemia. 2008 Jun 19. [Epub ahead of print] 6. Grossman SA, Carson
KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer
F, Supko JG; New Approaches to Brain Tumor Therapy CNS Consortium. Phase
I and pharmacokinetic study of karenitecin in patients with recurrent
malignant gliomas. Neuro Oncol. 2008 Jun 24. [Epub ahead of print] 7. Hucl T, Rago C, Gallmeier
E, Brody JR, Gorospe M, Kern SE. A syngeneic variance library for functional
annotation of human variation: application to BRCA2. Cancer Res. 2008
Jul 1;68(13):5023-30. 1. Emens LA. Cancer vaccines:
on the threshold of success. Expert Opin Emerg Drugs. 2008 Jun;13(2):295-308. 2. Farrar JE, Nater M,
Caywood E, McDevitt MA, Kowalski J, Takemoto CM, Talbot CC Jr, Meltzer
P, Esposito D, Beggs AH, Schneider HE, Grabowska A, Ball SE, Niewiadomska
E, Sieff CA, Vlachos A, Atsidaftos E, Ellis SR, Lipton JM, Gazda HT, Arceci
RJ. Abnormalities of the large ribosomal subunit protein, Rpl35A, in diamond-blackfan
anemia. Blood. 2008 Jun 5. [Epub ahead of print] 3. Huff CA, Matsui W.
Multiple myeloma cancer stem cells. J Clin Oncol. 2008 Jun 10;26(17):2895-900. 4. Loeb DM, Thornton
K, Shokek O. Pediatric soft tissue sarcomas. Surg Clin North Am. 2008
Jun;88(3):615-627. 5. Thornton K. Chemotherapeutic
management of soft tissue sarcoma. Surg Clin North Am. 2008 Jun;88(3):647-60. 6. Thornton K, Pesce
CE, Choti MA.Multidisciplinary management of metastatic sarcoma. Surg
Clin North Am. 2008 Jun;88(3):661-72. 1. Choi YB, Nicholas J. Autocrine and Paracrine
Promotion of Cell Survival and Virus Replication by Human Herpesvirus-8
Chemokines. J Virol. 2008 Apr 23. [Epub ahead of print] 2. Pratz K, Levis M. Incorporating FLT3 inhibitors
into acute myeloid leukemia treatment regimens. Leuk Lymphoma. 2008 May;49(5):852-63. 1. Gillison ML, D'Souza
G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor
profiles for human papillomavirus type 16-positive and human papillomavirus
type 16 negative head and neck cancers. J Natl Cancer Inst. 2008 Mar 11;
[Epub ahead of print] 2. Grossman SA, Olson J, Batchelor T, Peereboom
D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin
on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol.
2008 Feb 20; [Epub ahead of print] 3. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt
S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee
E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting
tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic
pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
Clin Cancer Res. 2008 Mar 1;14(5):1455-63. 4. Rudin CM, Liu W, Desai A, Karrison T, Jiang X,
Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL,
Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain
MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
J Clin Oncol. 2008 Mar 1;26(7):1119-27. 5. Wagner-Johnston ND, Ambinder RF. Blood
and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol.
2008 Mar;20(2):201-5. Review. 1. Jimeno A, Messersmith WA, Lee CK, Ma WW, Laheru
D, Donehower RC, Baker SD, Hidalgo M. Phase I study of troxacitabine administered
by continuous infusion in subjects with advanced solid malignancies. Ann
Oncol. 2008 Feb;19(2):374-9. 2. Li L, Piloto O, Nguyen HB, Greenberg K, Takamiya
K, Racke F, Huso D, Small D. Knock-in of an internal tandem duplication
mutation into murine FLT3 confers myeloproliferative disease in a mouse
model. Blood. 2008 Feb 1; [Epub ahead of print] 3. Piantadosi S. Rigor in monitoring clinical trials
is ethical. J Clin Oncol. 2008 Feb 1;26(4):683-5. 4. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett
M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski
J. Research issues affecting preoperative systemic therapy for operable
breast cancer. J Clin Oncol. 2008 Feb 10;26(5):806-13. Review. 1. Abukhdeir AM, Vitolo
MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin 2. Aggarwal S, Brennen WN, Kole TP, Schneider E,
Topaloglu O, Yates M, Cotter RJ, 3. Bechan GI, Meeker AK, Marzo AM, Racke F, Jaffe
R, Sugar E, Arceci RJ.Telomere length shortening in Langerhans cell histiocytosis.
Br J Haematol. 2007 Dec 19; [Epub ahead of print] 4. Griffiths EA, Gore SD.DNA methyltransferase and
histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Semin Hematol. 2008 Jan;45(1):23-30. 5. Matsui W, Wang Q, Barber JP, Brennan S,
Smith BD, Borrello I, McNiece I, Lin 1. Antonarakis ES, Blackford
AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic
prostate cancer treated with hormone therapy: a quantitative systematic
review. J Clin Oncol. 2007 Nov 1;25(31):4998-5008. Review. 2. Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G,
Hayward SD. Modulation of LMP1 protein expression by EBV-encoded microRNAs.
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9. Epub 2007 Oct 2. 3. Mirmonsef P, Tan G, Zhou G, Morino T, Noonan
K, Borrello I, Levitsky HI. Escape from suppression: tumor-specific effector
cells outcompete regulatory T cells following stem cell transplantation.
Blood. 2007 Dec 6; [Epub ahead of print] 4. Pardoll DM. Building the bionic T cell.
Nat Med. 2007 Dec;13(12):1411-3. No abstract available. 1. Friedman AD. Normal
and malignant hematopoiesis. Oncogene. 2007 Oct 15;26(47):6686. 2. Friedman AD.Transcriptional control of granulocyte
and monocyte development. Oncogene. 2007 Oct 15;26(47):6816-28. 3. Lauring J, Abukhdeir AM, Konishi H, Garay JP,
Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH. The multiple myeloma-associated
MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Blood. 2007 Oct 17; [Epub ahead of print] 4. Platz EA. Epidemiologic musing on statin
drugs in the prevention of advanced prostate cancer. Cancer Epidemiol
Biomarkers Prev. 2007 Nov 2; [Epub ahead of print] 1. Basch EM, Somerfield MR, Beer TM, Carducci
MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology
endorsement of the cancer care Ontario Practice Guideline on nonhormonal
therapy for men with metastatic hormone-refractory (castration-resistant)
prostate cancer. J Clin Oncol. 2007 Oct 9; [Epub ahead of print] 2. Bastian PJ, Palapattu GS, Yegnasubramanian S,
Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson
WG. Prognostic value of preoperative serum cell-free circulating DNA in
men with prostate cancer undergoing radical prostatectomy. Clin Cancer
Res. 2007 Sep 15;13(18):5361-5367. 3. Bolanos-Meade J, Garrett-Mayer E, Luznik L, Anders
V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon
YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB.
Induction of autologous graft-versus-host disease: results of a randomized
prospective clinical trial in patients with poor risk lymphoma. Biol Blood
Marrow Transplant. 2007 Oct;13(10):1185-91. 4. Brandes JC, Carraway H, Herman JG. Optimal primer
design using the novel primer design program: MSPprimer provides accurate
methylation analysis of the ATM promoter. Oncogene. 2007 Sep 13;26(42):6229-37.
5. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu
F, Liu Z, Rustgi AK, Herman JG. Epigenetic silencing of CDX2 is a feature
of squamous esophageal cancer. Int J Cancer. 2007 Sep 15;121(6):1219-26. 6. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski
M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau
F, Yu H, Pardoll DM, Drake CG. Cutting edge: An in vivo requirement for
STAT3 signaling in TH17 development and TH17-dependent autoimmunity. 7. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue
CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin
(MSLN) is attributable to an upstream enhancer containing a transcription
enhancer factor dependent MCAT motif. Cancer Res. 2007 Oct 1;67(19):9055-65. 8. Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza
P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M; Children's Oncology
Group. Analysis of biologic surrogate markers from a Children's Oncology
Group Phase I trial of gefitinib in pediatric patients with solid tumors.
Pediatr Blood Cancer. 2007 Sep;49(3):352-7. 9. Kern SE, Shibata D. The fuzzy math of solid tumor
stem cells: a perspective. Cancer Res. 2007 Oct 1;67(19):8985-8. 10. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD,
Matsui W, Jones RJ. Induction of acute lymphocytic leukemia differentiation
by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-20. 11. Liu J, Martin HJ, Liao G, Hayward SD. The Kaposi's
sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc.
J Virol. 2007 Oct;81(19):10451-9. 12. Nava-Parada P, Emens LA. GV-1001, an injectable
telomerase peptide vaccine for the treatment of solid cancers. Curr Opin
Mol Ther. 2007 Oct;9(5):490-7. 13. Ryu B, Kim DS, Deluca AM, Healey MA, Dunlap
S, Fackler MJ, Herman J, Alani RM. Id1 expression is transcriptionally
regulated in radial growth phase melanomas. Int J Cancer. 2007 Oct 15;121(8):1705-9. 14. Zong JC, Arav-Boger R, Alcendor DJ, Hayward
GS. Reflections on the interpretation of heterogeneity and strain differences
based on very limited PCR sequence data from Kaposi's sarcoma-associated
herpesvirus genomes. J Clin Virol. 2007 Sep;40(1):1-8. 15. Zong JC, Kajumbula H, Boto W, Hayward
GS. Evaluation of global clustering patterns and strain variation over
an extended ORF26 gene locus from Kaposi's sarcoma herpesvirus. 1. Friedman AD. C/EBPalpha
induces PU.1 and interacts with AP-1 and NF-kappaB to regulate myeloid
development. Blood Cells Mol Dis. 2007 Jul 30; [Epub ahead of print] 2. Sandler HM, Eisenberger MA. Assessing and treating
patients with increasing prostate specific antigen following radical prostatectomy.
J Urol. 2007 Jul 16; [Epub ahead of print] 1. Howerton MW, Bell
BS, Dodd KW, Berrigan D, Stolzenberg-Solomon R, Nebeling L. School-based
Nutrition Programs Produced a Moderate Increase in Fruit and Vegetable
Consumption: Meta and Pooling Analyses from 7 Studies. J Nutr Educ Behav.
2007 Jul-Aug;39(4):186-96. 2. Lin TL, Vala MS, Barber JP, Karp JE, Smith BD,
Matsui W, Jones RJ. Induction of acute lymphocytic leukemia differentiation
by maintenance therapy. Leukemia. 2007 Jul 5; [Epub ahead of print] 3. Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive
expression profiling of tumor cell lines identifies molecular signatures
of melanoma progression. PLoS ONE. 2007 Jul 4;2:e594. 1. Davidson NE. The maturation of medical oncology. Lancet Oncol. 2007
Jun;8(6):457-8. 1. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo
N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. The incidence and clinical
significance of nucleophosmin mutations in childhood
AML. Blood. 2007 Apr 17; [Epub ahead of print] 2. Casero RA Jr, Marton LJ. Targeting polyamine
metabolism and function in cancer and other hyperproliferative diseases.
Nat Rev Drug Discov. 2007 May;6(5):373-90. 3. Jimeno A, Hallur G, Chan A, Zhang X, Cusatis
G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M.
Development of two novel benzoylphenylurea sulfur analogues and evidence
that the microtubule-associated protein tau is predictive of their activity
in pancreatic cancer. Mol Cancer Ther. 2007 May 4; [Epub ahead of print]
4. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith
WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I
and pharmacokinetic study of UCN-01 in combination with irinotecan in
patients with solid tumors. Cancer Chemother Pharmacol. 2007 Apr 12; [Epub
ahead of print] 5. Nelson WG, Yegnasubramanian S, Agoston AT, Bastian
PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics,
and prostate cancer. Front Biosci. 2007 May 1;12:4254-66. 6. Ohm JE, Baylin SB. Stem cell chromatin patterns:
an instructive mechanism for DNA hypermethylation? Cell Cycle. 2007 May;6(9):1040-3.
Epub 2007 May 28. 7. Zhou S, Kachhap S, Sun W, Wu G, Chuang
A, Poeta L, Grumbine L, Mithani SK, Chatterjee A, Koch W, Westra WH, Maitra
A, Glazer C, Carducci M, Sidransky D, McFate T, Verma A, Califano JA.
Frequency and phenotypic implications of mitochondrial DNA mutations in
human squamous cell cancers of the head and neck. Proc Natl Acad Sci U
S A. 2007 May 1;104(18):7540-5. Epub 2007 Apr 24. 1. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll
RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, Lansdorp PM,
Greider CW, Loyd JE. Telomerase mutations in families with idiopathic
pulmonary fibrosis. N Engl J Med. 2007 Mar 29;356(13):1317-26.
2. Jimeno A, Rudek MA, Purcell T, Laheru DA,
Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower
RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan
in patients with solid tumors. Cancer Chemother Pharmacol. 2007 Apr 12;
[Epub ahead of print] 1. Bolanos-Meade J, Vogelsang GB. Montelukast in
chronic graft-versus-host disease: a breath of fresh air? Transplantation.
2007 Mar 15;83(5):527-8. No abstract available. 2. Fu DX, Tanhehco YC, Chen J, Foss CA, Fox JJ,
Lemas V, Chong JM, Ambinder RF, Pomper MG. Virus-associated tumor imaging
by induction of viral gene expression. Clin Cancer Res. 2007 Mar 1;13(5):1453-8.
3. Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir
K, Kasparkova J, Brabec V, Bachman KE, Kern SE. High-throughput screening
identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient
cancer cells. Cancer Res. 2007 Mar 1;67(5):2169-77. 4. Hann CL, Rudin CM. Fast, hungry and unstable:
finding the Achilles' heel of small-cell lung cancer. Trends Mol Med.
2007 Feb 24; [Epub ahead of print] 5. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang
X, Kincaid E, Chen R, Clark DP, Forastiere A, Hidalgo M. Dual EGFR and
mTOR targeting in squamous cell carcinoma models, and development of early
markers of efficacy. Br J Cancer. 2007 Mar 6; [Epub ahead of print] 6. Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald
V, Maitra A, Iacobuzio-Donahue C, Hidalgo M. Dual mitogen-activated protein
kinase and epidermal growth factor receptor inhibition in biliary and
pancreatic cancer. Mol Cancer Ther. 2007 Mar;6(3):1079-88. 7. Klein AP, de Andrade M, Hruban RH, Bondy M, Schwartz
AG, Gallinger S, Lynch 8. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz
IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins
DN, Matsui W. Hedgehog signaling maintains a tumor stem cell compartment
in multiple myeloma. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53.
Epub 2007 Feb 27. 9. Pledgie-Tracy A, Sobolewski MD, Davidson NE.
Sulforaphane induces cell type-specific apoptosis in human breast cancer
cell lines. Mol Cancer Ther. 2007 Mar;6(3):1013-21. Epub 2007 Mar 5. 10. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs
JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming
toxin as therapy for prostatic disease. 1. Georgantas RW 3rd, Hildreth R, Morisot S, Alder
J, Liu CG, Heimfeld S, Calin GA, Croce CM, Civin CI. CD34+ hematopoietic
stem-progenitor cell microRNA expression and function: A circuit diagram
of differentiation control. Proc Natl Acad Sci U S A. 2007 Feb 9; [Epub
ahead of print] 2. Gillison ML. Current topics in the epidemiology
of oral cavity and oropharyngeal cancers. Head Neck. 2007 Jan 17; [Epub
ahead of print] 3. Kasamon YL. Blood or marrow transplantation for
mantle cell lymphoma. Curr Opin Oncol. 2007 Mar;19(2):128-35. 4. Walczak JR, Carducci MA. Prostate cancer: a practical
approach to current management of recurrent disease. Mayo Clin Proc. 2007
Feb;82(2):243-9. 5. Zhou G, Levitsky HI. Natural regulatory T cells
and de novo-induced regulatory T cells contribute independently to tumor-specific
tolerance. J Immunol. 2007 Feb 15;178(4):2155-62. 1. Diehl F, Diaz LA Jr. Digital quantification of
mutant DNA in cancer patients. Curr Opin Oncol.
2007 Jan;19(1):36-42. 2. Gallmeier E, Kern SE. Targeting Fanconi Anemia/BRCA2
Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic
Models. Clin Cancer Res. 2007 Jan 1;13(1):4-10. 3. Gillison ML, Chen R, Goshu E, Rushlow D, Chen
N, Banister C, Creek KE, Gallie BL. Human retinoblastoma is not caused
by known pRb-inactivating human DNA tumor viruses. Int J Cancer. 2007
Jan 4; [Epub ahead of print] 4. Hayward GS, Zong JC. Modern evolutionary history
of the human KSHV genome. Curr Top Microbiol Immunol. 2007;312:1-42. Review.
5. Howerton MW, Gibbons MC, Baffi CR, Gary TL, Lai
GY, Bolen S, Tilburt J, Tanpitukpongse TP, Wilson RF, Powe NR, Bass EB,
Ford JG. Provider roles in the recruitment of underrepresented populations
to cancer clinical trials. Cancer. 2007 Jan 2; [Epub ahead of print] 6. Hudspeth MP, Raymond GV. Immunopathogenesis of
adrenoleukodystrophy: Current understanding. J Neuroimmunol. 2007 Jan;182(1-2):5-12.
Epub 2006 Nov 27. 7. Jones RJ, Matsui W. Cancer Stem Cells: From Bench
to Bedside. Biol Blood Marrow Transplant. 2007 Jan;13S1:47-52. 8. Kasamon YL, Jones RJ, Wahl RL. Integrating PET
and PET/CT into the Risk-Adapted Therapy of Lymphoma. J Nucl Med. 2007
Jan;48(1_suppl):19S-27S. 9. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins
C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous
weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with
solid tumours. Eur J Cancer. 2007 Jan;43(1):78-86. Key words: BPU, solid
tumors 10. Nicholas J. Human herpesvirus 8-encoded
proteins with potential roles in virus-associated neoplasia Front Biosci.
2007 Jan 1;12:265-81. 1. Babbar N, Casero RA Jr. Tumor Necrosis Factor-{alpha}
Increases Reactive Oxygen Species by Inducing Spermine Oxidase in Human
Lung Epithelial Cells: A Potential Mechanism
for Inflammation-Induced Carcinogenesis. Cancer Res. 2006 Dec 1;66(23):11125-30.
2. Cheong I, Huang X, Bettegowda C, Diaz LA Jr,
Kinzler KW, Zhou S, Vogelstein 3. Gerber DE, Grossman SA, Zeltzman M, Parisi MA,
Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation
in newly diagnosed adults with high-grade gliomas. Neuro-oncol. 2006 Nov
15; [Epub ahead of print] 4. Hudspeth MP, Raymond GV. Immunopathogenesis of
adrenoleukodystrophy: Current understanding. J Neuroimmunol. 2006 Nov
22; [Epub ahead of print] 5. Williams SA, Singh P, Isaacs JT, Denmeade SR.
Does PSA play a role as a promoting agent during the initiation and/or
progression of prostate cancer? Prostate. 2006 Dec 1; [Epub ahead of print]
1. Carducci MA, Jimeno A. Targeting bone metastasis
in prostate cancer with endothelin receptor antagonists. Clin Cancer Res.
2006 Oct 15;12(20 Pt 2):6296s-6300s. 2. Guo M, House MG, Akiyama Y, Qi Y, Capagna D,
Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA
gene family in esophageal cancer. Int J Cancer. 2006 Nov 1;119(9):2078-83.
3. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ,
Jones RJ. Reply to 'Quantification of marrow CD34+ cells: an important
tool for distinguishing between hypoplastic myelodysplastic syndromes
and aplastic anemia' by A Orazi. Leukemia. 2006 Nov;20(11):2041-2. Epub
2006 Sep 14. No abstract available. 4. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins
C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Phase I study of continuous
weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with
solid tumours. Eur J Cancer. 2006 Nov 2; [Epub ahead of print] 5. Stearns V. Raloxifene and tamoxifen had similar
efficacy for preventing invasive breast cancer in women at increased risk.
ACP J Club. 2006 Nov-Dec;145(3):72. 6. Stearns V, Schneider B, Henry NL, Hayes
DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors
and emerging genetic determinants. Nat Rev Cancer. 2006 Nov;6(11):886-93.
Epub 2006 Oct 12. 1. Armstrong DK, Brady MF. Intraperitoneal therapy
for ovarian cancer: a treatment ready for prime
time. J Clin Oncol. 2006 Oct 1;24(28):4531-3. No abstract available. 2. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern
SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase
(TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine
therapy. Cancer Res. 2006 Oct 1;66(19):9369-73. 3. Chen D, Nicholas J. Structural requirements for
gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence
for gp80 stabilization of gp130 signaling complexes induced by vIL-6.
J Virol. 2006 Oct;80(19):9811-21. 4. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ,
Jones RJ. Reply to 'Quantification of marrow CD34+ cells: an important
tool for distinguishing between hypoplastic myelodysplastic syndromes
and aplastic anemia' by A Orazi. Leukemia. 2006 Sep 14; [Epub ahead of
print] 5. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart
DA. Breast cancer treatment and ovarian failure: risk factors and emerging
genetic determinants. Nat Rev Cancer. 2006 Oct 12; [Epub ahead of print]
6. Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS,
Argani P, Sukumar S. HOXB7, a homeodomain protein, is overexpressed in
breast cancer and confers epithelial-mesenchymal transition. Cancer Res.
2006 Oct 1;66(19):9527-34. 7. Zahnow CA. ErbB receptors and their ligands
in the breast. Expert Rev Mol Med. 2006 Sep 20;8(23):1-21. 1. Abukhdeir AM, Blair BG, Brenner K, Karakas B,
Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo
MI, Bachman KE, Park BH. Physiologic estrogen receptor
alpha signaling in non-tumorigenic human mammary epithelial cells. Breast
Cancer Res Treat. 2006 Sep;99(1):23-33. 2. Carducci MA, Musib L, Kies MS, Pili R, Truong
M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha
V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic
study of enzastaurin, an oral protein kinase C beta inhibitor, in patients
with advanced cancer. J Clin Oncol. 2006 Sep 1;24(25):4092-9. 3. Drake CG. Basic overview of current immunotherapy
approaches in urologic malignancy. Urol Oncol. 2006 Sep-Oct;24(5):413-8.
4. Georgantas RW 3rd, Bohana-Kashtan O, Civin CI.
Ex vivo soluble fas ligand treatment of donor cells to selectively reduce
murine acute graft versus host disease. Transplantation. 2006 Aug 27;82(4):471-8.
5. Grossman SA, Carson KA, Batchelor TT, Lesser
G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG.
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics
and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006
Sep 1;12(17):5174-81. 6. Hu F, Nicholas J. Signal transduction by human
Herpesvirus 8 viral Interleukin-6 (vIL-6) is modulated by the non-signaling
gp80 subunit of the IL-6 receptor complex and is distinct from signaling
induced by human IL-6. J Virol. 2006 Sep 6 [Epub ahead of print]. 7. Juergens R, Brahmer J, Ettinger D. Gemcitabine
and vinorelbine in recurrent advanced non-small cell lung cancer: sequence
does matter. Cancer Chemother Pharmacol. 2006 Aug 26; [Epub ahead of print]
8. Powell JD. The induction and maintenance of T
cell anergy. Clin Immunol. 2006 Sep;120(3):239-46. 9. Rudek MA, Zhao M, He P, Messersmith WA, Baker
SD. Validation and implementation of a liquid chromatography/tandem mass
spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751
sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed
Anal. 2006 Sep 18;42(2):253-60. 10. Zhao M, Rudek MA, Mnasakanyan A, Hartke
C, Pili R, Baker SD. A liquid chromatography/tandem mass spectrometry
assay to quantitate MS-275 in human plasma. 1. Brown P, Levis M,
McIntyre E, Griesemer M, Small D. Combinations of the FLT3 inhibitor CEP-701
and chemotherapy synergistically kill infant and childhood MLL-rearranged
ALL cells in a sequence-dependent manner. Leukemia. 2006 Aug;20(8):1368-76.
Epub 2006 Jun 8. 2. Ettinger DS, Bepler
G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg
SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG,
Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood
DE; National Comprehensive Cancer Network (NCCN). Non-small cell lung
cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw.
2006 Jul;4(6):548-82. 3. Gardner ER, Burger H, van Schaik RH, van Oosterom
AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE,
Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and
transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol
Ther. 2006 Aug;80(2):192-201. 4. Gibson MK, Forastiere AA. Reassessment of the
role of induction chemotherapy for head and neck cancer. Lancet Oncol.
2006 Jul;7(7):565-74. Review. 5. Guo M, House MG, Akiyama Y, Qi Y, Capagna D,
Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA
gene family in esophageal cancer. Int J Cancer. 2006 Jul 5; [Epub ahead
of print] 6. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman
JG. Accumulation of promoter methylation suggests epigenetic progression
in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006 Aug
1;12(15):4515-22. 7. Johnson BE, Crawford J, Downey RJ, Ettinger DS,
Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas
M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams
CC Jr; National Comprehensive Cancer Network (NCCN). Small cell lung cancer
clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006
Jul;4(6):602-22. 8. Kim KT, Levis M, Small D. Constitutively activated
FLT3 phosphorylates BAD partially through Pim-1. Br J Haematol. 2006 Jul
26; [Epub ahead of print] 9. Ndovi TT, Choi L, Caffo B, Parsons T, Baker S,
Zhao M, Rohde C, Hendrix CW. Quantitative assessment of seminal vesicle
and prostate drug concentrations by use of a noninvasive method. Clin
Pharmacol Ther. 2006 Aug;80(2):146-58. 10. Pfister DG, Laurie SA, Weinstein GS, Mendenhall
WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison
LB, Lefebvre JL, Leupold N, List MA, O'Malley BO, Patel S, Posner MR,
Schwartz MA, Wolf GT. American Society of Clinical Oncology clinical practice
guideline for the use of larynx-preservation strategies in the treatment
of laryngeal cancer. J Clin Oncol. 2006 Aug 1;24(22):3693-704. Epub 2006
Jul 10. 12. Sciubba DM, Mavinkurve GG, Gailloud P, Garonzik
IM, Recinos PF, McGirt MJ, Woodworth GF, Witham T, Khavkin Y, Gokaslan
ZL, Wolinsky JP. Preoperative imaging of cervical spine hemangioblastomas
using three-dimensional fusion digital subtraction angiography: report
of two cases. J Neurosurg Spine. 2006 Jul;5(1):96-100. 13. Wong AS, Soo RA, Lu JJ, Loh KS, Tan KS, Hsieh
WS, Shakespeare TP, Chua ET, Lim HL, Goh BC. Paclitaxel, 5-fluorouracil
and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal
carcinoma. Ann Oncol. 2006 Jul;17(7):1152-1157. Epub 2006 May 9. 1. Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy
B, Bader JS, Pandey A, Cole PA. Phosphoproteomic analysis of Her2/neu
signaling and inhibition. Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9773-9778.
Epub 2006 Jun 19. 2. Brandes JC, Herman JG, Hodge DR, Farrar WL. p53
Expression after Treatment with Zebularine Is Not Due to Demethylation.
Cancer Res. 2006 Jul 1;66(13):6892-3. 4. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B,
Dressman D. BEAMing: single molecule PCR on microparticles in water-in-oil
emulsions. Nat Methods. 2006 Jul;3(7):551-9. 7. Guo M, House MG, Akiyama Y, Qi Y, Capagna D,
Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA
gene family in esophageal cancer. Int J Cancer. 2006 Jul 5; [Epub ahead
of print] 11. Rubio-Viqueira B, Hidalgo M. Targeting mTOR
for cancer treatment. Curr Opin Investig Drugs. 2006 Jun;7(6):501-12.
1. Ettinger DS. Clinical implications of EGFR expression
in the development and progression of solid
tumors: focus on non-small cell lung cancer. Oncologist. 2006 Apr;11(4):358-73.
2. Hess AD, Thoburn CJ. Immune tolerance to self-major
histocompatability complex class II antigens after bone marrow transplantation:
role of regulatory T cells. Biol Blood Marrow Transplant. 2006 May;12(5):518-29.
3. Huff CA, Matsui WH, Douglas Smith B, Jones RJ.
Strategies to eliminate cancer stem cells: Clinical implications. Eur
J Cancer. 2006 Jun;42(9):1293-7. Epub 2006 Apr 27. 4. Karakas B, Weeraratna A, Abukhdeir A, Blair BG,
Konishi H, Arena S, Becker 5. Kern SE, Winter JM. Elegance, silence and nonsense
in the mutations literature for solid tumors. Cancer Biol Ther. 2006 Apr;5(4):349-59.
Epub 2006 Apr 1. 6. Powell JD. The induction and maintenance of T
cell anergy. Clin Immunol. 2006 Mar 30; [Epub ahead of print] 7. Wang D, D'Costa J, Civin CI, Friedman AD. C/EBP{alpha}
directs monocytic commitment of primary myeloid progenitors. Blood 2006
Apr 27; [Epub ahead of print] 1. Abukhdeir AM, Blair BG, Brenner K, Karakas B,
Konishi H, Lim J, Sahasranaman 2. Aggarwal S, Harden JL, Denmeade SR. Synthesis
and screening of a random dimeric peptide library using the one-bead-one-dimer
combinatorial approach. Bioconjug Chem. 2006 Mar-Apr;17(2):335-40. 3. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics
of docetaxel : recent developments. Clin Pharmacokinet. 2006;45(3):235-52.
4. Cope L, Hartman SM, Gohlmann HW, Tiesman JP,
Irizarry RA. Analysis of Affymetrix GeneChip data using amplified RNA.
Biotechniques. 2006 Feb;40(2):165-6, 168, 170. 5. Garrett-Mayer E. The continual reassessment method
for dose-finding studies: a tutorial. Clin Trials. 2006;3(1):57-71. 6. Hallur G, Jimeno A, Dalrymple S, Zhu T, Jung
MK, Hidalgo M, Isaacs JT, Sukumar S, Hamel E, Khan SR. Benzoylphenylurea
sulfur analogues with potent antitumor activity. J Med Chem. 2006 Apr
6;49(7):2357-60. 7. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive
protein levels and subsequent cancer outcomes: Results from a prospective
cohort study. Eur J Cancer. 2006 Apr;42(6):704-707. Epub 2006 Mar 2. 8. Jimeno A. Race, gender and mutations in the prediction
of anti-EGFR activity. Future Oncol. 2005 Apr;1(2):201-4. 9. Kato Y, Okollie B, Artemov D. Noninvasive 1H/13C
magnetic resonance spectroscopic imaging of the intratumoral distribution
of temozolomide. Magn Reson Med. 2006 Apr;55(4):755-61. 10. Kern SE, Winter JM. Elegance, Silence
and Nonsense in the Mutations Literature for Solid Tumors. Cancer Biol
Ther. 2006 Apr 1;5(4) 1. Baylin SB, Ohm JE. Epigenetic gene silencing
in cancer - a mechanism for early oncogenic
pathway addiction? Nat Rev Cancer. 2006 Feb;6(2):107-16. Review. 2. Bolanos-Meade J. Update on the management of
acute graft-versus-host disease. 3. Jimeno A, Kulesza P, Kincaid E, Bouaroud N, Chan
A, Forastiere A, Brahmer J, 4. Karakas B, Bachman KE, Park BH. Mutation of the
PIK3CA oncogene in human cancers. Br J Cancer. 2006 Feb 27;94(4):455-9.
5. Li J, Brahmer J, Messersmith W, Hidalgo M, Baker
SD. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine
kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
Invest New Drugs. 2006 Feb 17; [Epub ahead of print] 6. Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K,
Prouser T, Jalla S, Zhou X, Garrett-Mayer E, Kaufmann SH, Schulick RD,
Pardoll DM, Bedi A. Resistance of cancers to immunologic cytotoxicity
and adoptive immunotherapy via X-linked inhibitor of apoptosis protein
expression and coexisting defects in mitochondrial death signaling. Cancer
Res. 2006 Feb 1;66(3):1730-9. 7. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade
SR, Ball DW, Nelkin BD. Activity of irinotecan and the tyrosine kinase
inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab.
2006 Jan;91(1):79-84. 8. Zilliox MJ, Parmigiani G, Griffin DE. Gene expression
patterns in dendritic cells infected with measles virus compared with
other pathogens. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3363-3368.
1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen
R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group.
Intraperitoneal cisplatin and paclitaxel in
ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. 2. Basaria S, Muller DC, Carducci MA, Egan J, Dobs
AS. Hyperglycemia and insulin resistance in men with prostate carcinoma
who receive androgen-deprivation therapy. Cancer. 2006 Feb 1;106(3):581-8.
3. Huang J, Liao G, Chen H, Wu FY, Hutt-Fletcher
L, Hayward GS, Hayward SD. Contribution of C/EBP proteins to Epstein-Barr
virus lytic gene expression and replication in epithelial cells. J Virol.
2006 Feb;80(3):1098-109. 4. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox
of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-4.
Epub 2005 Sep 8. Review. 5. Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee
I, Yen RW, Baylin SB, Schuebel KE. De novo CpG island methylation in human
cancer cells. Cancer Res. 2006 Jan 15;66(2):682-92. 6. Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza
P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M. Analysis of biologic
surrogate markers from a Children's Oncology Group Phase I trial of gefitinib
in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Jan
19 [Epub ahead of print]. 7. Karakas B, Bachman KE, Park BH. Mutation of the
PIK3CA oncogene in human cancers. Br J Cancer. 2006 Jan 31 [Epub ahead
of print]. 8. Mathew BS, Carson KA, Grossman SA. Initial response
to glucocorticoids. Cancer. 2006 Jan 15;106(2):383-7. 9. Modzelewska A, Pettit C, Achanta G, Davidson
NE, Huang P, Khan SR. Anticancer activities of novel chalcone and bis-chalcone
derivatives. Bioorg Med Chem. 2006 Jan 21
11. Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura
K, Prouser T, Jalla S, Zhou X, Garrett-Mayer E, Kaufmann SH, Schulick
RD, Pardoll DM, Bedi A. Resistance of cancers to immunologic cytotoxicity
and adoptive immunotherapy via x-linked inhibitor of apoptosis protein
expression and coexisting defects in mitochondrial death signaling. Cancer
Res. 2006 Feb 1;66(3):1730-9. 12. Serafini P, Borrello I, Bronte V. Myeloid suppressor
cells in cancer: Recruitment, phenotype, properties, and mechanisms of
immune suppression. Semin Cancer Biol. 2006 Feb;16(1):53-65. Epub 2005
Sep 15.
14. Zheng R, Small D. Mutant FLT3 signaling contributes
to a block in myeloid differentiation. Leuk Lymphoma. 2005 Dec;46(12):1679-87.
15. Zhou G, Drake CG, Levitsky HI. Amplification
of tumor-specific regulatory T cells following therapeutic cancer vaccines.Blood.
2006 Jan 15;107(2):628-36. 1. Basaria S, Muller DC, Carducci MA, Egan J, Dobs
AS. Hyperglycemia and insulin resistance in men with prostate carcinoma
who receive androgen-deprivation therapy. Cancer 2005 Dec 30 ;106(3):581-588
[Epub ahead of print]. 2. Baylin SB. DNA methylation and gene silencing
in cancer. Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1(S1):S4-S11. 3. Diaz-Montes TP, Ji H, Smith Sehdev AE, Zahurak
ML, Kurman RJ, Armstrong DK, 4. Emens LA. Towards a therapeutic breast cancer
vaccine: the next steps. Expert Rev Vaccines. 2005 Dec;4(6):831-41. 5. Hempen PM, Kurpad H, Calhoun ES, Abraham S, Kern
SE. Erratum: A double missense variation of the BUB1 gene and a defective
mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T.
Hum Mutat. 2005 Dec;26(6):592. 6. Karikari CA, Mullendore M, Eshleman JR, Argani
P, Leoni LM, Chattopadhyay S, 7. Lee BH, Yegnasubramanian S, Lin X, Nelson WG.
Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol
Chem. 2005 Dec 9;280(49):40749-56. 8. Levis M. FLT3 and acute myeloid leukemia: what
is the wild type receptor up to? 9. Li J, Orlandi R, White CN, Rosenzweig J, Zhao
J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET,
Chan DW. Independent validation of candidate breast cancer serum biomarkers
identified by mass spectrometry. Clin Chem. 2005 Dec;51(12):2229-35. 10. Mathew BS, Carson KA, Grossman SA. Initial response
to glucocorticoids. Cancer 2005 Dec 9;106(2):383-387. 11. Messersmith W, Oppenheimer D, Peralba J, Sebastiani
V, Amador M, Jimeno A, 12. Okoye ME, Sexton GL, Huang E, McCaffery JM,
Desai P. Functional analysis of the triplex proteins (VP19C and VP23)
of herpes simplex virus type 1. J Virol. 2006 Jan;80(2):929-40. 13. Pledgie A, Huang Y, Hacker A, Zhang Z, Woster
PM, Davidson NE, Casero RA 14. Powell JD, Fitzhugh C, Kang EM, Hsieh M, Schwartz
RH, Tisdale JF. Low-Dose Radiation Plus Rapamycin Promotes Long-Term Bone
Marrow Chimerism. Transplantation 2005 Dec 15;80(11):1541-1545. 15. Zheng R, Small D. Mutant FLT3 signaling contributes
to a block in myeloid differentiation. Leuk Lymphoma. 2005 Dec;46(12):1679-87.
1. D'Souza G, Sugar E, Ruby W, Gravitt
P, Gillison M. Analysis of the effect of DNA purification on detection
of human papillomavirus in oral rinse samples by PCR. J Clin Microbiol
2005;43(11):5526-5535. 2. Laheru D, Yeo CJ. Role of adjuvant therapy
in the management of pancreatic cancer. Adv Surg 2005;39:223-244. 3. Matsui W. Expanding the toolbox of myeloma
biology. Haematologica 2005;90(11):1448. 4. van der Heijden MS, Brody JR, Dezentje
DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff
WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi
anemia/BRCA2 status of the tumor. Clin Cancer Res 2005;11(20):7508-7515. 5. Whartenby KA, Calabresi PA, McCadden E,
Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D. Inhibition
of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl
Acad Sci USA 20052005 Nov 15;102(46):16741-16746. Epub 2005 Nov 4. 1. Germain-Lee EL, Schwindinger W, Crane JL, Zewdu
R, Zweifel LS, Wand G, Huso DL, Saji M, Ringel MD, Levine MA. A mouse
model of albright hereditary osteodystrophy generated by targeted disruption
of exon 1 of the Gnas gene. Endocrinology 2005 Aug 11; [Epub ahead of
print] 2. Hu G, Mancl ME, Barnes BJ. Signaling through
IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced
apoptosis and cell death. Cancer Res 2005; 65 (16): 7403-12. 3. Jimeno A, Hidalgo M. Promises and pitfalls in
the prediction of antiepidermal growth factor receptor activity. Expert
Rev Anticancer Ther 2005; 5 (4): 727-35. 4. Jimeno A, Toledo T, Moya I, Gonzalez-Barber A.
Chronic disseminated intravascular coagulation caused by an aorto-bifemoral
aneurysm. Eur J Intern Med 2005;16 (4): 298-300. 5. Maitra A, Arking DE, Shivapurkar N, Ikeda
M, Stastny V, Kassauei K, Sui G, Cutler DJ, Liu Y, Brimble SN, Noaksson
K, Hyllner J, Schulz TC, Zeng X, Freed WJ, Crook J, Abraham S, Colman
A, Sartipy P, Matsui SI, Carpenter M, Gazdar AF, Rao M, Chakravarti A.
Genomic alterations in cultured human embryonic stem cells. Nat Genet.
2005 Sep 4; [Epub ahead of print] 1. Davidson NE, O'Neill
A M, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine
therapy for premenopausal women with axillary lymph node-positive, steroid
hormone receptor-positive breast cancer: Results from INT 0101 (E5188J).
Clin Oncol 2005 Aug 15; [Epub ahead of print] 2. Diaz-Montes TP, Zahurak ML, Giuntoli RL, 2nd,
Gardner GJ, Gordon TA, Armstrong DK, Bristow RE. Surgical care of elderly
women with ovarian cancer: A population-based perspective. Gynecol Oncol.
2005 Jul 28; [Epub ahead of print] 3. Fujimuro M, Liu J, Zhu J, Yokosawa H, Hayward
SD. Regulation of the interaction between glycogen synthase kinase 3 and
the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear
antigen. J Virol 2005;79(16):10429-10441. 4. Gallmeier E, Kern SE. Absence of specific cell
killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose)
polymerase inhibition. Cancer Biol Ther 2005;4(7). 5. Hughes MA, Parisi M, Grossman S, Kleinberg
L. Primary brain tumors treated with steroids and radiotherapy: Low CD4
counts and risk of infection. Int J Radiat Oncol Biol Phys 2005; 62(5):1423-1426. 1. Adjei AA, Hidalgo M. Intracellular signal transduction
pathway proteins as targets for cancer therapy. J J Clin Oncol. 2005 Jun
27; [Epub ahead of print] 2. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI,
Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle
KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ. Phase II trial of temsirolimus
(CCI-779) in ecurrent glioblastoma multiforme: North Central Cancer Treatment
Group. J Clin Oncol. 2005 Jul 5; [Epub ahead of print] 3. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci
MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Marimastat in the treatment
of patients with biochemically relapsed prostate cancer: a prospective
randomized, double-blind, phase I/II trial. Clin Cancer Res 2005 Jun 15;11(12):4437-43 1. Brandes JC, van Engeland M, Wouters KA, Weijenberg
MP, Herman JG. CHFR promoter hypermethylation in colon cancer correlates
with the microsatellite instability phenotype. Carcinogenesis. 2005 Jun;26(6):1152-6. 2. Browner I, and Carducci MA. Palliative chemotherapy:
historical perspective, applications, and controversies. Semin Oncol 2005;32:145-55. 3. D'Costa J, Chaudhuri S, Civin CI, Friedman AD.
CBFbeta-SMMHC slows proliferation of primary murine and human myeloid
progenitors. Leukemia 2005;19:921-9. 10. Zambidis ET, Peault B, Park TS, Bunz F, Civin
CI. Hematopoietic differentiation of human embryonic stem cells progresses
through sequential hemato-endothelial, primitive, and definitive stages
resembling human yolk sac development. Blood. 2005 Apr 14; [Epub ahead
of print] 1. Armstrong AJ, Carducci MA. Chemotherapy for advanced
prostate cancer: results of new clinical trials and future studies. Curr
Oncol Rep 2005;7(3):220-227. 2. Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden
A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang
GB. Pentostatin in steroid-refractory acute graft-versus-host disease.
J Clin Oncol 2005;23(12):2661-2668. 3. Chen S, Watson P, Parmigiani G. Accuracy of MSI
testing in predicting germ line mutations of MSH2 and MLH1: a case study
in Bayesian meta-analysis of diagnostic tests without a gold standard.
Biostatistics 2005. 4. Galm O, Suzuki H, Akiyama Y, Esteller M, Brock
MV, Osieka R, Baylin SB, Herman JG. Inactivation of the tissue inhibitor
of metalloproteinases-2 gene by promoter hypermethylation in lymphoid
malignancies. Oncogene. 2005 May 2; [Epub ahead of print]. 5. Khan SR, Kumar SK, Farquhar D. Bis(carbamoyloxymethyl)
esters of 2',3'-dideoxyuridine 5'-monophosphate (ddUMP) as potential ddUMP
prodrugs. Pharm Res 2005;22(3):390-396. 6. Khan SR, Nowak B, Plunkett W, Farquhar D. Bis(pivaloyloxymethyl)
thymidine 5'-phosphate is a cell membrane-permeable precursor of thymidine
5'-phosphate in thymidine kinase deficient CCRF CEM cells. Biochem Pharmacol
2005;69(9):1307-1313. 7. Lengauer C, Diaz LA, Saha S. Outlook: Cancer
drug discovery through collaboration. Nat Rev Drug Discov 2005;4(5):375-380. 8. Molina H, Parmigiani G, Pandey A. Assessing reproducibility
of a protein dynamics study using in vivo labeling and liquid chromatography
tandem mass spectrometry. Analyt Chem 2005;77(9):2739-2744. 9. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M,
Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H,
Ball DW. Regulation of neuroendocrine differentiation in gastointestinal
carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 2005
May 3; [Epub ahead of print]. 10. Nanda A, Rizzo JD, Vogelsang GB. A case of retroperitoneal
fibrosis in a patient following HSCT. Bone Marrow Transplant 2005 Jun;35(11):1125-6. 11. Safford M, Collins S, Lutz MA, Allen A, Huang
CT, Kowalski J, Blackford A, Horton MR, Drake C, Schwartz RH, Powell JD.
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol
2005;6(5):472-480. 12. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang
L, Fansler Z, Clark D, Nakanishi O, Pili R. Epigenetic modulation of retinoic
acid receptor {beta}2 by the histone deacetylase inhibitor MS-275 in human
renal cell carcinoma. Clin Cancer Res 2005;11(9) :3535-3542. 1. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward
MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang
AY. Multicenter, phase II study of cetuximab in combination with carboplatin
in patients with recurrent or metastatic nasopharyngeal carcinoma. 2. D'Costa J, Chaudhuri S, Civin CI, Friedman AD.
CBFbeta-SMMHC slows proliferation of primary murine and human myeloid
progenitors. Leukemia 2005. In press. 3. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher
E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell
L, Nelson WG, Pardoll DM, Adler AJ. Androgen ablation mitigates tolerance
to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005 7(3):239-49. 4. Emens LA, Reilly RT, Jaffee EM. Breast cancer
vaccines: maximizing cancer treatment by tapping into host immunity. Endocr
Relat Cancer 2005;12(1):1-17. 5. Levis M, Murphy KM, Pham R, Kim KT, Stine A,
Li L, McNiece I, Smith BD, Small D. Internal tandem duplications of the
FLT3 gene are present in leukemia stem cells. Blood 2005. In press. 6. Peters BA, Diaz LA, Polyak K, Meszler L, Romans
K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler
KW, Lengauer C. Contribution of bone marrow-derived endothelial cells
to human tumor vasculature. Nat Med 2005;11(3):261-262. 7. Rudek MA, Hartke C, Zabelina Y, Zhao M, New P,
Baker SD. A sensitive method for determination of COL-3, a chemically
modified tetracycline, in human plasma using high-performance liquid chromatography
and ultraviolet detection. J Pharm Biomed Annal 2005;37(4):751-6. 8. Wang Y, Hacker A, Murray-Stewart T, Frydman B,
Valasinas A, Fraser AV, Woster PM, Casero RA Jr. Properties of recombinant
human N(1)-acetylpolyamine oxidase (hPAO): potential role in determining
drug sensitivity. Cancer Chemother Pharmacol 2005. In press. 9. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early
transcription factor RTA encodes ubiquitin E3 ligase activity that targets
IRF7 for proteosome-mediated degradation. Immunity 2005;22(1):59-70. 10. Zhao M, Hartke C, Jimeno A, Li J, He P, ZabelinaY,
Hidalgo M, Baker SD. Specific method for determination of gefitinib in
human plasma, mouse plasma and tissues using high performance liquid chromatography
coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed
Life Sci 2005;819(1) :73-80. 1. Bohana-Kashtan O, Civin CI. Profiling tumor counterattack:
do Fas ligand-containing microvesicles reduce anticancer immunity? Clin
Cancer Res 2005;11:968-70. 2. Brandes JC, van Engeland M, Wouters KA, Weijenberg
MP, Herman JG. CHFR promoter hypermethylation in colon cancer correlates
with the microsatellite instability phenotype. Carcinogenesis 2005; Mar
10. In press. 3. Carducci MA. What is more exciting? The activity
of docetaxel in early prostate cancer or the successful collaboration
between urologists and medical oncologists to complete a study in early
prostate cancer? J Clin Oncol 2005; Feb 28. In press. 4. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase
II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic
small bowel adenocarcinoma. Oncologist 2005;10:132-7. 5. Hansel DE, Dhara S, Huang RC, Ashfaq R, Deasel
M, Shimada Y, Bernstein HS, Harmon J, Brock M, Forastiere A, Washington
MK, Maitra A, Montgomery E. CDC2/CDK1 expression in esophageal adenocarcinoma
and precursor lesions serves as a diagnostic and cancer progression marker
and potential novel drug target. Am J Surg Pathol 2005;29:390-399. 6. Noonan K, Matsui W, Serafini P, Carbley R, Tan
G, Khalili J, Bonyhadi M, Levitsky H, Whartenby K, Borrello I. Activated
marrow-infiltrating lymphocytes effectively target plasma cells and their
clonogenic precursors. Cancer Res 2005;65:2026-34. 1. Bettegowda C, Foss
CA, Cheong I, Wang Y, Diaz L, Agrawal N, Fox J, Dick J, Dang LH, Zhou
S, Kinzler KW, Vogelstein B, Pomper MG. Imaging bacterial infections with
radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil.
Proc Natl Acad Sci U S A 2005;102(4):1145-50. 2. Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson
SB, Aylesworth C, Elza-Brown K, Carducci MA, Donehower RC. A Phase I and
pharmacokinetic study of short infusions of UCN-01 in patients with refractory
solid tumors. Clin Cancer Res 2005;11(2 Pt1):664-71. 3. Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic
target: making a "smart bomb" for prostate cancer. Cancer Biol
Ther 2005;4(1). 4. Diaz LA, Jr. The current clinical value of genomic
instability. Semin Cancer Biol 2005;15(1):67-71. 5. Matsubayashi H, Sato N, Brune K, Blackford AL,
Hruban RH, Canto M, Yeo CJ, Goggins M. Age- and disease-related methylation
of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin
Cancer Res 2005;11(2 Pt 1):573-83. 6. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta
can mediate growth arrest and differentiation via the leukemia inhibitory
factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine
2005;29(3):125-34. 7. Shabbeer S, Carducci MA. Focus on deacetylation
for therapeutic benefit. IDrugs 2005;8(2):144-54. 8. Zhao M, Rudek MA, He P, Smith BD, Baker SD. Validation
and implementation of a method for determination of bryostatin 1 in human
plasma by using liquid chromatography/tandem mass spectrometry. Anal Biochem
2005;337(1):143-8. 9. Zhou X, Jun do Y, Thomas AM, Huang X, Huang LQ,
Mautner J, Mo W, Robbins PF, Pardoll DM, and Jaffee EM. Diverse CD8+ T-Cell
responses to renal cell carcinoma antigens in patients treated with an
autologous granulocyte-macrophage colony-stimulating factor gene-transduced
renal tumor cell vaccine. Cancer Res 2005;65(3):1079-88. 1. Bachman KE, Park BH.
Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter.
Curr Opin Oncol 2005;17(1):49-54. 2. Chen WY, Baylin SB. Inactivation of tumor suppressor
genes: Choice between genetic and epigenetic routes. Cell Cycle 2005:4(1)
[Epub ahead of print]. 3. Lengauer C. Aneuploidy and genetic instability
in cancer. Semin Cancer Biol 2005;15(1), 1. 4. Levis M. Recent advances in the development of
small-molecule inhibitors for the treatment of acute myeloid leukemia.
Curr Opin Hematol 2005;12 (1): 55-61. 5. Liao G, Huang J, Fixman ED, Hayward SD. The Epstein-Barr
virus replication protein BBLF2/3 provides an origin-tethering function
through interaction with the zinc finger DNA binding protein ZBRK1 and
the KAP-1 corepressor. J Virol 2005;79(1):245-56. 6. Park JI, Powers JF, Tischler AS, Strock CJ, Ball
DW, Nelkin BD. GDNF-induced leukemia inhibitory factor can mediate differentiation
via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous
knockout mice. Exp Cell Res 2005;303(1), 79-88. 7. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta
can mediate growth arrest and differentiation via the leukemia inhibitory
factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine
2005;29(3), 125-34. 8. Qian, D. Z., Ren, M., Wei, Y., Wang, X., van
de Geijn, F., Rasmussen, C., Nakanishi, O., Sacchi, N., and Pili, R. In
vivo imaging of retinoic acid receptor beta2 transcriptional activation
by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate
cancer cells. Prostate 2005 [Epub ahead of print]. 9. Sun LQ, Arceci R J. Altered epigenetic patterning
leading to replicative senescence and reduced longevity: a role of a novel
SNF2 factor, PASG.Cell Cycle 2005;4(1 [Epub ahead of print]). 1. Bastian PJ, Yegnasubramanian
S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Molecular biomarker
in prostate cancer: the role of CpG island hypermethylation. Eur Urol
2004;46:698-708. 2. Chen P, Levis M, Brown P, Kim KT, Allebach J,
Small D. FLT3/ITD mutation signaling includes suppression of SHP-1. J
Biol Chem 2004 Dec 1 [Epub ahead of print]. 3. Gore SD. Inhibitors of signaling in myelodysplastic
syndrome. Best Pract Res Clin Haematol 2004;17:613-622. 4. Higman M, Vogelsang GB, Chen A. Pentostatin -
pharmacology, immunology, and clinical effects in graft-versus-host disease.
Expert Opin Pharmacother 2004;5:2605-2613. 5. Jimeno A, Carducci M. Atrasentan: targeting the
endothelin axis in prostate cancer. Expert Opin Investig Drugs 2004;13:1631-1640. 6. Kim EJ, Park JI, Nelkin BD. IFI16 is an essential
mediator of growth inhibition, but not differentiation, induced by the
leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma
cells. J Biol Chem 2004 [Epub ahead of print]. 7. Kohli M, Yu J, Seaman C, Bardelli A, Kinzler
KW, Vogelstein B, Lengauer C, Zhang L. SMAC/Diablo-dependent apoptosis
induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer
cells. Proc Natl Acad Sci U S A 2004;101:16897-16902. 8. Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari
H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN, Jr. A New High affinity
technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
Bioconjug Chem 2004;15:1416-1423. 9. Litvinov IV, Antony L, Isaacs JT. Molecular characterization
of an improved vector for evaluation of the tumor suppressor versus oncogene
abilities of the androgen receptor. Prostate 2004:61(4):299-304. 10. Nanda A, Buckhaults P, Seaman S, Agrawal N,
Boutin P, Shankara S, Nacht M, Teicher B, Stampfl J, Singh S, Vogelstein
B, Kinzler KW, St Croix B. Identification of a binding partner for the
endothelial cell surface proteins TEM7 and TEM7R. Cancer Res 2004;64:8507-8511. 11. Nelson WG. Agents in development for prostate
cancer prevention. Expert Opin Investig Drugs 2004;13:1541-1554. 12. Rajagopalan H, Lengauer C. Aneuploidy and cancer.
Nature 2004;432:338-341. 13. Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci
MA, Baker SD. Quantification of 5-azacytidine in plasma by electrospray
tandem mass spectrometry coupled with high-performance liquid chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:81-88. 1. Chen W, Cooper TK,
Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder
JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB. Epigenetic and genetic
loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer
Cell 2004;6:387-398. 2. Huang CT, Workman CJ, Flies D, Pan X, Marson
AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll
DM, Drake CG, Vignali DA. Role of LAG-3 in regulatory T cells. Immunity
2004;21:503-513. 3. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M,
Levis M, Small D. Pim-1 is upregulated by constitutively activated FLT3
and plays a role in FLT3-mediated cell survival. Blood 2004. In press.
4. Lee JM, Lee KH, Farrell CJ, Ling PD, Kempkes
B, Park JH, Hayward SD. EBNA2 is required for protection of latently epstein-barr
virus-infected B cells against specific apoptotic stimuli. J Virol 2004;78:12694-12697. 5. Lengauer C, Wang Z. From spindle checkpoint to
cancer. Nat Genet 2004;36:1144-1145. 6. Mock V, Frangakis C, Davidson NE, Ropka ME, Pickett
M, Poniatowski B, Stewart KJ, Cameron L, Zawacki K, Podewils LJ, Cohen
G, McCorkle R. Exercise manages fatigue during breast cancer treatment:
A randomized controlled trial. Psychooncology 2004. In press. 7. Nelson WG. Prostate cancer prevention. J Nutr
2004;134:3211S-3212S. 8. Pardoll D, Allison J. Translation of cancer immunotherapies.
Nat Med 2004;10:1155. 9. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand
SD, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, Nacht M, Teicher
BA, Klinger KW, Sukumar S, Madden SL. Alterations in vascular gene expression
in invasive breast carcinoma. Cancer Res 2004;64:7857-7866. 10. Samuels Y, Velculescu VE. Oncogenic mutations
of PIK3CA in human cancers. Cell Cycle 2004;3.(10). In Press. 1. Agrawal N, Bettegowda C, Cheong
I, Geschwind JF, Drake CG, Hipkiss EL, Tatsumi M, Dang LH, Diaz LA, Jr.,
Pomper M, Abusedera M, Wahl RL, Kinzler KW, Zhou S, Huso DL, Vogelstein
B. Bacteriolytic therapy can generate a potent immune response against
experimental tumors. Proc Natl Acad Sci U S A 2004. 2. Brodsky RA, Jones RJ. Riddle: what do aplastic
anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have
in common? Leukemia 2004;18:1740-1742. 3. Brody JR, Kern SE. History and principles of
conductive media for standard DNA electrophoresis. Annal Biochem 2004;333:1-13. 4. Brody JR, Kern SE. Stagnation and Herd Mentality
in the Biomedical Sciences. Cancer Biol Ther 2004;3. 5. Hayward SD. Viral interactions with the Notch
pathway. Semin Cancer Biol 2004;14:387-396. 6. Kasamon YL, Swinnen LJ: Treatment advances in
adult Burkitt lymphoma and leukemia. Curr Opin Oncol 2004;16:429-435. 7. Messersmith WA, Laheru DA, Senzer NN, Donehower
RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, Hidalgo M: Phase
I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (folfiri)
with erlotinib (osi-774): early termination due to increased toxicities.
Clin Cancer Res 2004;10:6522-6527. 8. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang
L, Atadja P, Pili R. The histonedeacetylase inhibitor NVP-LAQ824 inhibits
angiogenesis and has a greater antitumor effect in combination with the
vascular endothelial growth factor receptor tyrosine kinase inhibitor
PTK787/ZK222584. Cancer Res 2004;64:6626-6634. 9. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs
WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP. Prostate cancer detection
on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol
2004;172:1501-1503. 10. Samuels Y, Velculescu VE: Oncogenic Mutations
of PIK3CA in Human Cancers. Cell Cycle 2004;3. 11. Thoburn CJ, Miura Y, Bright EC, Hess AD: Functional
divergence of antigen-specific T- lymphocyte responses in syngeneic graft-versus-host
disease. Biol Blood Marrow Transplant 2004;10:591-603. 12. Watkins DN, Peacock CD: Hedgehog signalling
in foregut malignancy. Biochem Pharmacol 2004;68:1055-1060. 1. Alce TM, Popik W. APOBEC3G is incorporated into
virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid
protein. J Biol Chem 2004; 279:34083-34086. 2. Armanios MY, Grossman
SA, Yang SC, White B, Perry A, Burger PC, Orens JB. Transmission of glioblastoma
multiforme following bilateral lung transplantation from an affected donor:
case study and review of the literature. Neuro-oncol. 2004 Jul;6(3):259-63. 3. Bachman KE, Argani P, Samuels Y, Silliman N,
Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu
VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast
cancers. Cancer Biol Ther 2004;3. In press. 4. Barnes BJ, Richards J, Mancl ME, Hanash S, Beretta
L, Pitha PM. Global and specific targets of IRF-5 and IRF-7 during innate
response to viral infection. J Biol Chem 2004. In press. 5. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange
J, Lapides A, Garrett E, Argani P, Sukumar S. Quantitative multiplex methylation-specific
PCR assay for the detection of promoter hypermethylation in multiple genes
in breast cancer. Cancer Res 2004;64:4442-4452. 6. Georgantas RW, 3rd, Tanadve V, Malehorn M, Heimfeld
S, Chen C, Carr L, Martinez-Murillo F, Riggins G, Kowalski J, Civin CI.
Microarray and serial analysis of gene expression analyses identify known
and novel transcripts overexpressed in hematopoietic stem cells. Cancer
Res 2004;64:4434-4441. 7. Jang YY, Sharkis SJ. Metamorphosis from bone
marrow derived primitive stem cells to functional liver cells. Cell Cycle
2004;3. 8. Kasamon YL, Swinnen
LJ. Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin
Oncol 2004;16:429-435. 9. Pardoll D, Allison
J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat
Med 2004;10:887-892. 10. Serafini P, Carbley
R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage
colony-stimulating factor-producing vaccines impair the immune response
through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-6343. 11. Thomas AM, Santarsiero LM, Lutz ER, Armstrong
TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific
CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting
cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306. 12. Ting AH, Jair KW, Suzuki H, Yen RW, Baylin SB,
Schuebel KE. Mammalian DNA methyltransferase 1: inspiration for new directions.
Cell Cycle 2004;3. 13. Uzgare AR, Isaacs JT. Enhanced redundancy
in Akt and mitogen-activated protein kinase-induced survival of malignant
versus normal prostate epithelial cells. Cancer Res 2004;64:6190-6199. 14. Vogelstein B, Kinzler KW. Cancer genes
and the pathways they control. Nat Med 2004;10:789-799. 1. Bartsch G, Fitzpatrick
JM, Schalken JA, Isaacs J, Nordling J, Roehrborn CG. Consensus statement:
the role of prostate-specific antigen in managing the patient with benign
prostatic hyperplasia. BJU Int 2004;93 Suppl 1:27-29. 2. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann
RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF. Azacitidine
induces demethylation of the Epstein-Barr Virus genome in tumors in patients.
J Clin Oncol 2004. 3. David GL, Yegnasubramanian S, Kumar A, Marchi
VL, De Marzo AM, Lin X, Nelson WG. MDR1 Promoter hypermethylation in MCF-7
human breast cancer cell: changes in chromatin structure induced by treatment
with 5-Aza-Cytidine. Cancer Biol Ther 2004;3(6). 4. Douglas DB, Akiyama Y, Carraway H, Belinsky SA,
Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB.
Hypermethylation of a small CpGuanine-rich region correlates with loss
of activator protein-2alpha expression during progression of breast cancer.
Cancer Res 2004;64(5):1611-20. 5. Farrell CJ, Lee JM, Shin EC, Cebrat M, Cole PA,
Hayward SD. Inhibition of Epstein-Barr virus-induced growth proliferation
by a nuclear antigen EBNA2-TAT peptide. Proc Natl Acad Sci U S A 2004. 6. Fuchs EJ, Whartenby KA. Hematopoietic stem cell
transplant as a platform for tumor immunotherapy. Curr Opin Mol Ther 2004;6(1):48-53. 7. Huang Y, Keen JC, Hager E, Smith R, Hacker A,
Frydman B, Valasinas AL, Reddy VK, Marton LJ, Casero RA, Jr., Davidson
NE. Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435
cancer cells. Mol Cancer Res 2004;2(2):81-8. 8. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML.
Gender differences in sexual biomarkers and behaviors associated with
human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 2004;31(4):247-256. 9. Parmigiani G. Uncertainty and the value of diagnostic
information, with application to axillary lymph node dissection in breast
cancer. Stat Med 2004;23(5):843-55. 10. Rajagopalan H, Jallepalli PV, Rago C, Velculescu
VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause
chromosomal instability. Nature 2004;428(6978):77-81. 11. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak
J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz
S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations
of the PIK3CA gene in human cancers. Science 2004. 12. Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics
in the treatment of breast cancer. Pharmacogenomics J 2004. 13. Suzuki H, Watkins DN, Jair KW, Schuebel KE,
Markowitz SD, Dong Chen W, Pretlow TP, Yang B, Akiyama Y, Van Engeland
M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic
inactivation of SFRP genes allows constitutive WNT signaling in colorectal
cancer. Nat Genet 2004. 14. Yegnasubramanian S, Kowalski J, Gonzalgo
ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB,
Nelson WG. Hypermethylation of CpG islands in primary and metastatic human
prostate cancer. Cancer Res 2004;64(6):1975-86. 1. Bachman KE, Blair BG, Brenner
K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH:
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial
cells. Cancer Biol Ther 2004;3(2). 2. Bernardin-Fried F, Kummalue T, Leijen S, Collector
MI, Ravid K, Friedman AD: ML1/RUNX1 increases during G1 to S cell cycle
progression independent of cytokine-dependent phosphorylation and induces
cyclin D3 gene expression. J Biol Chem 2004. 3. Cleaves R, Wang QF, Friedman AD: C/EBPalphap30,
a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not
terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding.
Oncogene 2004;23(3):716-25. 4. De Marzo AM, DeWeese TL, Platz EA, Meeker AK,
Nakayama M, Epstein JI, Isaacs WB, Nelson WG: Pathological and molecular
mechanisms of prostate carcinogenesis: Implications for diagnosis, detection,
prevention, and treatment. J Cell Biochem 2004;91(3):459-77. 5. Denmeade SR, Isaacs JT: Development of prostate
cancer treatment: The good news. Prostate 2004;58(3):211-24. 6. Iacobuzio-Donahue CA, Van Der Heijden MS, Baumgartner
MR, Troup WJ, Romm JM, Doheny K, Pugh E, Yeo CJ, Goggins MG, Hruban RH,
Kern SE: Large-scale allelotype of pancreaticobiliary carcinoma provides
quantitative estimates of genome-wide allelic loss. Cancer Res 2004;64(3):871-5. 7. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE,
Viscidi R, Garrett ES, Shah KV, Gillison ML: Oral human Papillomavirus
infection in adults is associated with sexual behavior and HIV serostatus.
J Infect Dis 2004;189(4):686-98. 8. Nanda A, Carson-Walter EB, Seaman S, Barber TD,
Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B: TEM8 interacts
with the cleaved C5 domain of collagen alpha3(VI). Cancer Res 2004;64(3):817-20. 9. Spira A, Ettinger DS: Multidisciplinary management
of lung cancer. N Engl J Med 2004;350(4):379-92. 10. Zheng R, Klang K, Gorin NC, Small D: Lack
of KIT or FMS internal tandem duplications but co-expression with ligands
in AML. Leuk Res 2004;28(2):121-6. 1. Amador ML, Jimeno
J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Progress in the development
and acquisition of anticancer agents from marine sources. Ann Oncol 2003;14(11):1607-15. 2. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA,
Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle
arrest and cell death. Cancer Res 2003;63(19):6424-31. 3. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra
J, Polyak K, Sukumar S, Argani P. DNA methylation of RASSF1A, HIN-1, RAR-beta,
Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
Int J Cancer 2003;107(6):970-5. 4. Fackler MJ, Evron E, Khan SA, Sukumar S. Novel
agents for chemoprevention, screening methods, and sampling issues. J
Mammary Gland Biol Neoplasia 2003;8(1):75-89. 5. Lassiter LK, Carducci MA. Endothelin receptor
antagonists in the treatment of prostate cancer. Semin Oncol 2003;30(5):678-88. 6. Levis M, Small D. FLT3, It does matter in leukemia.
Leukemia 2003;17(9):1738-52. Review 7. Liem RI, Higman MA, Chen AR, Arceci RJ. Misinterpretation
of a Calvert-derived formula leading to carboplatin overdose in two children.
J Pediatr Hematol Oncol 2003;25(10):818-21. 8. Miura Y, Ueda M, Takami A, Shiobara S, Nakao
S, Hess AD. Enhancement of cyclosporin A-induced autologous graft-versus-host
disease after peripheral blood stem cell transplantation by utilizing
selected CD34(+) cells. Bone Marrow Transplant 2003;32(8):785-90. 9. Schwartz CL. Prognostic factors in pediatric
Hodgkin disease. Curr Oncol Rep 2003;5(6):498-504. 10. Sikder H, Huso DL, Zhang H, Wang B, Ryu B, Hwang
ST, Powell JD, Alani RM. Disruption of Id1 reveals major differences in
angiogenesis between transplanted and autochthonous tumors. Cancer Cell
2003;4(4):291-9. 11. Spira A, Ettinger DS. Extensive-stage small-cell
lung cancer. Semin Surg Oncol 2003;21(3):164-75. 12.Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri
B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD. CEP-701 and CEP-751
inhibit constitutively activated RET tyrosine kinase activity and block
medullary thyroid carcinoma cell growth. Cancer Res 2003;63(17):5559-63. 13. Wolff AC. Liposomal anthracyclines and new treatment
approaches for breast cancer. Oncologist 2003;8 Suppl 2:25-30. 14. Wolff AC, Donehower RC, Carducci MK, Carducci
MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman
PA, Webb NL, Baker SD. Phase I study of docosahexaenoic acid-paclitaxel:
a taxane-fatty acid conjugate with a unique pharmacology and toxicity
profile. Clin Cancer Res 2003;9(10 Pt 1):3589-97. 15. Zheng R, Friedman AD, Levis M, Li L, Weir EG,
Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation
through suppression of C/EBP{alpha} expression. Blood 2003 [Epub ahead
of print]. 1. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones
RJ, Woolfrey A, Amylon M, Sullivan KM, Storb RF, Walters MC. Results of
minimally toxic nonmyeloablative transplantation in patients with sickle
cell anemia and beta-thalassemia. Biol Blood
Marrow Transplant 2003 Aug;9(8):519-28. 2. Kummalue T, Friedman AD. Cross-talk between regulators
of myeloid development: C/EBPalpha binds and activates the promoter of
the PU.1 gene. J Leukoc Biol 2003 Sep;74(3):464-70. 3. Malek SN, Hatfield AJ, Flinn IW. MALT Lymphomas.
Curr Treat Options Oncol 2003 Aug;4(4):269-79. 4. Malek SN, Flinn IW. Incorporating monoclonal
antibodies in blood and marrow transplantation. Semin Oncol 2003 Aug;30(4):520-30. 5. Nakayama M, Bennett CJ, Hicks JL, Epstein JI,
Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione
S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative
inflammatory atrophy lesions but not in normal or hyperplastic epithelium
of the prostate: a detailed study using laser-capture microdissection.
Am J Pathol 2003 Sep;163(3):923-33. 6. Nicholas J. Human herpesvirus-8-encoded signalling
ligands and receptors. J Biomed Sci 2003 Sep-Oct;10(5):475-89. 7. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer
C. The significance of unstable chromosomes in colorectal cancer. Nat
Rev Cancer 2003 Sep;3(9):695-701. 1. Ambinder RF. Posttransplant
lymphoproliferative disease: pathogenesis, monitoring, and therapy. Curr
Oncol Rep 2003 Sep;5(5):359-63. 2. Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix
B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih
IeM. Identifying tumor origin using a gene expression-based classification
map. Cancer Res 2003 Jul 15;63(14):4144-9. 3. Fahrner JA, Baylin SB. Heterochromatin: stable
and unstable invasions at home and abroad. Genes Dev 2003 Aug 1;17(15):1805-12. 4. Grunwald V, Hidalgo M. Development of the epidermal
growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol 2003;532:235-46. 5. Mahindra AK, Grossman SA. Pneumocystis carinii
pneumonia in HIV negative patients with primary brain tumors. J Neurooncol
2003 Jul;63(3):263-70. 6. Montgomery E, Wilentz RE, Argani P, Fisher C,
Hruban RH, Kern SE, Lengauer C. Analysis of anaphase figures in routine
histologic sections distinguishes chromosomally unstable from chromosomally
stable malignancies. Cancer Biol Ther 2003 May-Jun;2(3):248-52. 7. Parker BS, Cutts SM, Nudelman A, Rephaeli A,
Phillips DR, Sukumar S. Mitoxantrone mediates demethylation and reexpression
of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.
Cancer Biol Ther. 2003 May-Jun;2(3):259-63. 8. Smith BD, Karp JE. Ribonucleotide reductase:
an old target with new potential. Leuk Res 2003 Dec;27(12):1075-6. 9. Song DY, Jones RJ, Welsh
JS, Haulk TL, Korman LT, Noga S, Goodman S, Herman M, Mann R, Marcellus
D, Vogelsang G, Ambinder RF, Abrams RA. Phase I study of escalating doses
of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients
with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma. Int J
Radiat Oncol Biol Phys 2003 Sep 1;57(1):166-71. 10. Spira AI, Carducci MA. Differentiation therapy.
Curr Opin Pharmacol 2003 Aug;3(4):338-43. 11. Traverso G, Diehl F, Hurst R, Shuber A, Whitney
D, Johnson C, Levin B, Kinzler KW, Vogelstein B. Multicolor in vitro translation.
Nat Biotechnol 2003 Aug 10. 12. Ulutin HC, Zellars RC, Frassica D. Soft tissue
sarcoma of the vulva: A clinical study. Int J Gynecol Cancer 2003 Jul-Aug;13(4):528-31. 13. Zhao M, He P, Rudek MA, Hidalgo M, Baker SD.
Specific method for determination of OSI-774 and its metabolite OSI-420
in human plasma by using liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 2003 Aug 15;793(2):413-420. 14. Zhou X, Cui Y, Huang X, Yu Z, Thomas AM, Ye
Z, Pardoll DM, Jaffee EM, Cheng L. Lentivirus-mediated gene transfer and
expression in established human tumor antigen-specific cytotoxic T cells
and primary unstimulated T cells. Hum Gene Ther 2003 Jul 20;14(11):1089-105. 1. Abrams RA. Adjuvant
therapy for pancreatic adenocarcinoma: what have we learned since 1985?
Int J Radiat Oncol Biol Phys 2003 Jul 15;56(4 Suppl):3-9. 2. Ambinder RF. Viruses as potential targets for
therapy in HIV-associated malignancies. Hematol Oncol Clin North Am 2003
Jun;17(3):697-702, v-vi. 3. Brown DA, Ward RL, Buckhaults P, Liu T, Romans
KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN. MIC-1
serum level and genotype: associations with progress and prognosis of
colorectal carcinoma. Clin Cancer Res 2003 Jul;9(7):2642-2650. 4. Denmeade SR, Jakobsen CM, Janssen S, Khan SR,
Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated
thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer
Inst 2003 Jul 2;95(13):990-1000. 5. Devereux W, Wang Y, Stewart TM, Hacker A, Smith
R, Frydman B, Valasinas AL, Reddy VK, Marton LJ, Ward TD, Woster PM, Casero
RA. Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues
in human lung carcinoma cells. Cancer Chemother Pharmacol 2003 Jun 25 6. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein
B. Transforming single DNA molecules into fluorescent magnet ic particles
for detection and enumeration of genetic variations. Proc Natl Acad Sci
U S A. 2003 Jul 11 7. Fujimuro M, Hayward SD. The latency-associated
nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates
the activity of glycogen synthase kinase-3beta. J Virol 2003 Jul;77(14):8019-30. 8. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG.
Prostate cancer detection by GSTP1 methylation analysis of postbiopsy
urine specimens. Clin Cancer Res 2003 Jul;9(7):2673-7. 9. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ,
Lillemoe KD, Shulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba
II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A. Identification
of novel cellular targets in biliary tract cancers using global gene expression
technology. Am J Pathol 2003 Jul;163(1):217-29. 10. Huang Y, Hager ER, Phillips DL, Dunn VR, Hacker
A, Frydman B, Kink JA, Valasinas AL, Reddy VK, Marton LJ, Casero RA Jr,
Davidson NE. A novel polyamine analog inhibits growth and induces apoptosis
in human breast cancer cells. Clin Cancer Res 2003 Jul;9(7):2769-77. 11. Kumar SK, Hager E, Pettit C, Gurulingappa H,
Davidson NE, Khan SR. Design, synthesis, and evaluation of novel boronic-chalcone
derivatives as antitumor agents. J Med Chem 2003 Jul 3;46(14):2813-5. 12. Litvinov IV, De Marzo AM, Isaacs JT. Is the
achilles' heel for prostate cancer therapy a gain of function in androgen
receptor signaling? J Clin Endocrinol Metab 2003 Jul 1;88(7):2972-2982. 13. Rasmussen AK, Chatterjee A, Rasmussen LJ, Singh
KK. Mitochondria-mediated nuclear mutator phenotype in Saccharomyces cerevisiae.
Nucleic Acids Res 2003 Jul 15;31(14):3909-17. 14. Smith BD, Karp J, Burke P. Response to 'comparison
of "sequential" versus "standard" chemotherapy as
re-induction treatment, with or without cyclosporine, in refractory/relapsed
acute myeloid leukaemia (aml): results of the uk medical research council
aml-r trial'. Br J Haematol 2003 Jul;122(1):164-5. 1. Huff CA, Fuchs EJ,
Noga SJ, O'donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB,
Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ. Long-term follow-up
of T cell-depleted allogeneic bone marrow transplantation in refractory
multiple myeloma: Importance of allogeneic T cells. Biol Blood Marrow
Transplant 2003 May;9(5):312-9. 2. Loeb DM, Summers JL, Burwell EA, Korz D, Friedman
AD, Sukumar S. An isoform of the Wilms' tumor suppressor gene potentiates
granulocytic differentiation. Leukemia 2003 May;17(5):965-71. 3. Nimmerjahn F, Milosevic S, Behrends U, Jaffee
EM, Pardoll DM, Bornkamm GW, Mautner J. Major histocompatibility complex
class II-restricted presentation of a cytosolic antigen by autophagy.
Eur J Immunol 2003 May;33(5):1250-9. 4. Ryu B, Kern SE. The essential similarity of TGFbeta
and activin receptor transcriptional responses in cancer cells. Cancer
Biol Ther 2003 Mar- Apr;2(2):164-70 5. Van Der Heijden MS, Yeo CJ, Hruban RH, Kern SE.
Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer
Res 2003 May 15;63(10):2585-8. 6. Volpert OV, Alani RM. Wiring the angiogenic switch:
Ras, Myc, and Thrombospondin-1. Cancer Cell 2003 Mar;3(3):199-200. 7. Wang QF, Cleaves R, Kummalue T, Nerlov C, Friedman
AD. Cell cycle inhibition mediated by the outer surface of the C/EBPalpha
basic region is required but not sufficient for granulopoiesis. Oncogene
2003 May 1;22(17):2548-57. 1. Akpek G, Lee SJ, Flowers
ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu
A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB. Performance
of a new clinical grading system for chronic graft-versus-host disease:
a multi-center study. Blood 2003 Apr 24 PMID: 12714524 2. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo
S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein
B, Velculescu VE. Mutational analysis of the tyrosine kinome in colorectal
cancers. Science 2003 May 9;300(5621):949. 3. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H,
Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth
of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Prostate 2003 Jun 15;56(1):45-53. 4. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman
JL, Wagner H, Gilbert M, Newton HB, Hellman R. Phase III study comparing
three cycles of infusional carmustine and cisplatin followed by radiation
therapy with radiation therapy and concurrent carmustine in patients with
newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative
Oncology Group Trial 2394. J Clin Oncol 2003 Apr 15;21(8):1485-91. 5. Hess AD, Thoburn CJ, Chen W, Bright AE. Unexpected
T-cell diversity in syngeneic graft-versus-host disease revealed by interaction
with peptide-loaded soluble MHC class II molecules. Transplantation 2003
Apr 27;75(8):1361-7. 6. Kleinberg L, Knisely JP, Heitmiller
R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Mature survival
results with preoperative cisplatin, protracted infusion 5-fluorouracil,
and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol
Phys 2003 Jun 1;56(2):328-34. 7. Lengauer C. Cancer. An unstable liaison. Science
2003 Apr 18;300(5618):442-3. 8. Olivi A, Grossman SA, Tatter S, Barker F, Judy
K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S. Dose escalation of
carmustine in surgically implanted polymers in patients with recurrent
malignant glioma: a new approaches to brain tumor therapy CNS consortium
trial. J Clin Oncol 2003 May 1;21(9):1845-9. 9. Reese BE, Bachman KE, Baylin SB, Rountree MR.
The methyl-CpG binding protein MBD1 interacts with the p150 subunit of
chromatin assembly factor 1. Mol Cell Biol 2003 May;23(9):3226-36. 10. Wang QF, Cleaves R, Kummalue
T, Nerlov C, Friedman AD. Cell cycle inhibition mediated by the outer
surface of the C/EBPalpha basic region is required but not sufficient
for granulopoiesis. Oncogene 2003 May 1;22(17):2548-57. 11. Wang Y, Murray-Stewart T, Devereux W, Hacker
A, Frydman B, Woster PM, Casero RA. Properties of purified recombinant
human polyamine oxidase, PAOh1/SMO. Biochem Biophys Res Commun 2003 May
16;304(4):605-611. 12. Watkins DN, Berman DM, Baylin SB. Hedgehog signaling:
progenitor phenotype in small-cell lung cancer. Cell Cycle 2003 May-Jun;2(3):196-8. 13. Zhou S, Kachhap S, Singh KK. Mitochondrial
impairment in p53-deficient human cancer cells. Mutagenesis 2003 May;18(3):287-92.
1. Casero RA, Wang Y,
Stewart TM, Devereux W, Hacker A, Wang Y, Smith R, Woster PM. The
role of polyamine catabolism in anti-tumour drug response. Biochem Soc
Trans. 2003 Apr 1;31(2):361-365. 2. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL.
Enhanced radiation and chemotherapy-mediated cell killing of human cancer
cells by small inhibitory RNA silencing of DNA repair factors. Cancer
Res 2003 Apr 1;63(7):1550-4. 3. Ercolini AM, Machiels JP, Chen YC, Slansky JE,
Giedlen M, Reilly RT, Jaffee EM. Identification and characterization of
the immunodominant rat HER-2/neu MHC Class I epitope presented by spontaneous
mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003 Apr 15;170(8):4273-80. 4. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman
JL, Wagner H, Gilbert M, Newton HB, Hellman R. Phase III study comparing
three cycles of infusional carmustine and cisplatin followed by radiation
therapy with radiation therapy and concurrent carmustine in patients with
newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative
Oncology Group trial 2394. J Clin Oncol. 2003 Apr 15;21(8):1485-91. 5. Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin
SB, Herman JG, Tlsty TD. Methylation of p16(INK4a) promoters occurs in
vivo in histologically normal human mammary epithelia, Cancer Res 2003
Apr 1;63(7):1596-601. 6. Huang CT, Huso DL, Lu Z, Wang T, Zhou G, Kennedy
EP, Drake CG, Morgan DJ, Sherman LA, Higgins AD, Pardoll DM, Adler AJ.
CD4(+) T Cells pass through an effector phase during the process of in
vivo tolerance induction. J Immunol 2003 Apr 15;170(8):3945-3953. 7. Jallepalli PV, Lengauer C, Vogelstein B, Bunz
F. The Chk2 tumor suppressor is not required for p53 responses in human
cancer cells. J Biol Chem 2003 Mar 24 [epub ahead of print] 8. Kominsky SL, Argani P, Korz D, Evron E, Raman
V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S. Loss of the
tight junction protein claudin-7 correlates with histological grade in
both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Oncogene. 2003 Apr 3;22(13):2021-33. 9. Matsui W, Huff CA, Vala M, Barber J, Smith BD,
Jones RJ. Anti-tumour activity of interferon-alpha in multiple myeloma:
role of interleukin 6 and tumor cell differentiation. Br J Haematol. 2003
Apr;121(2):251-8. 10. Parker B, Sukumar S. Distant metastasis in breast
cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther
2003 Jan-Feb;2(1):14-21. 11. Reese BE, Bachman KE, Baylin SB, Rountree MR.
The Methyl-CpG binding protein MBD1 interacts with the p150 subunit of
chromatin assembly factor 1. Mol Cell Biol 2003 May;23(9):3226-36. 12. Scharpf R, Garrett ES, Hu J, Parmigiani G. Statistical
modeling and visualization of molecular profiles in cancer. Biotechniques
2003 Mar;Suppl:22-9. 1. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young
DB, Hayward GS, Hayward SD. A novel viral mechanism for dysregulation
of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat
Med. 2003 Mar;9(3):300-6 2. Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue
CA, Murphy KM, Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson
JK, Yeo CJ, Hruban RH, Kern SE. Evidence of Selection for Clones Having
Genetic Inactivation of the Activin A Type II Receptor (ACVR2) Gene in
Gastrointestinal Cancers. Cancer Res. 2003 Mar 1;63(5):994-9 3. Lin X, Nelson WG Methyl-CpG-binding domain protein-2
mediates transcriptional repression associated with hypermethylated GSTP1
CpG islands in MCF-7 breast cancer cells. Cancer Res. 2003 Jan 15;63(2):498-504 4. Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky
HI, Pardoll DM, Fuchs EJ. Successful therapy of metastatic cancer using
tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003 Feb
15;101(4):1645-52 5. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J,
Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA. Suppression of prostate
cancer induced bone remodeling by the endothelin receptor A antagonist
atrasentan. J Urol. 2003 Mar;169(3):1143-9 6. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003 Mar 1;63(5):1114-21 7. Watkins DN, Berman DM, Burkholder SG, Wang B,
Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors
and in small-cell lung cancer. Nature. 2003 Mar 5; [epub ahead of print]
8. Yan F, Collector MI, Tyszko S, and Sharkis S.
Using divisional history to measure hematopoietic stem cell self-renewal
and differentiation. Exp. Hematol. 2003;31:56-64 9. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang
L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells.
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1931-6
Return to top of Publications - Oncology Archives
|
 |
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
JHM Appointments | Employment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM |
|
|
